XL518

Development Status

A Phase 1 clinical trial evaluating XL518 for solid tumors is ongoing.

Description

XL518 is a selective inhibitor of MEK, a key component of the MAP kinase pathway, which is frequently activated in human tumors. Activation of the pathway is required for transmission of growth-promoting signals from numerous receptor tyrosine kinases.

XL518 reached its maximum tolerated dose in an ongoing phase 1 trial, and is being transferred to our partner Genentech for further clinical development.

Information on Clinical Trials

Information about ongoing clinical trials of Exelixis' investigational product candidates is available at ClinicalTrials.gov, a service of the U.S. National Institutes of Health. General information about clinical trials and issues related to participating in clinical trials also is available at ClinicalTrials.gov.

Related Publications

For publication information related to this compound, please see the Related Publications page.